Cargando…

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

OBJECTIVES: Immune-checkpoint inhibitors (ICIs) combined with chemotherapy are more widely used than monotherapy and have shown better survival in patients with advanced non-small cell lung cancer (NSCLC) without oncogenic driver alterations. The monocyte-to-lymphocyte ratio (MLR) might predict the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Liang, Xiong, Anning, Wang, Shuyuan, Xu, Jianlin, Shen, Yinchen, Zhong, Runbo, Lu, Jun, Chu, Tianqing, Zhang, Wei, Li, Ying, Zheng, Xiaoxuan, Han, Baohui, Zhong, Hua, Nie, Wei, Zhang, Xueyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909005/ https://www.ncbi.nlm.nih.gov/pubmed/36776882 http://dx.doi.org/10.3389/fimmu.2023.1094378

Ejemplares similares

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
por: Xiong, Anning, et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy
por: Shen, Yinchen, et al.
Publicado: (2020)

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
por: Li, Changhui, et al.
Publicado: (2021)

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?
por: Lou, Yuqing, et al.
Publicado: (2020)

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
por: Lu, Jun, et al.
Publicado: (2023)

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer
por: Chen, Dongfang, et al.
Publicado: (2020)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
por: Yu, Lian, et al.
Publicado: (2022)

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
por: Chu, Tianqing, et al.
Publicado: (2022)

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs
por: Zhang, Hai, et al.
Publicado: (2020)

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy
por: Chu, Tianqing, et al.
Publicado: (2023)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
por: Zhang, Bo, et al.
Publicado: (2022)

Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns
por: Hu, Fang, et al.
Publicado: (2019)

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer
por: Yu, Lian, et al.
Publicado: (2021)

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
por: Qiao, Rong, et al.
Publicado: (2019)

Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
por: Qiao, Rong, et al.
Publicado: (2017)

Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
por: Zhang, Xueyan, et al.
Publicado: (2018)

Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
por: Qiang, Huiping, et al.
Publicado: (2022)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients
por: Xiong, Anning, et al.
Publicado: (2021)

Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma
por: Shen, Yinchen, et al.
Publicado: (2019)

The satisfiability problem /
Publicado: (1999)

Unbalanced but Satisfied?
por: Shenoi, Asha N.
Publicado: (2016)

Easily Satisfied!
Publicado: (1898)

Satisfying journey!
por: Manohar, Balaji
Publicado: (2015)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab
por: Shen, Yinchen, et al.
Publicado: (2022)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

A model of mucopolysaccharidosis type IIIB in pigs
por: Yang, Qiang, et al.
Publicado: (2018)

Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines
por: Chen, Hongwei, et al.
Publicado: (2019)

Cliques, coloring, and satisfiability
por: Johnson, David S, et al.
Publicado: (1996)

Satisfy Your Appetite
Publicado: (1889)

A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
por: Bang, Sun-Hwi, et al.
Publicado: (2012)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

In vivo evaluation of an innovative synbiotics on stage IIIb-IV chronic kidney disease patients
por: Vacca, Mirco, et al.
Publicado: (2023)

Satisfied or not satisfied? Electronic health records system implementation in Ghana: Health leaders’ perspective
por: Attafuah, Priscilla Y. A., et al.
Publicado: (2022)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
por: Lu, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sh5dllpiis3u9gt51e3e5fr2vf